plugin/skills/tooluniverse-stem-cell-organoid/SKILL.md
Stem cell, iPSC, and organoid research — pluripotency markers, differentiation protocol pathways, lineage commitment factors, organoid model selection. Use for iPSC characterization, differentiation protocol design via developmental-pathway recapitulation, and organoid-model selection for disease modeling.
npx skillsauth add mims-harvard/tooluniverse tooluniverse-stem-cell-organoidInstall this skill globally with one command. Works with Claude Code, Cursor, and Windsurf.
3 of 9 scanners reported clean
Some scanners were skipped, did not run, or reported a non-clean status. Review each row below.
Pipeline for investigating stem cell biology, iPSC characterization, organoid models, and cell differentiation using ToolUniverse tools.
Stem cell differentiation follows developmental biology — to make any target cell type from iPSCs, the protocol must mimic the embryonic signaling pathway that generates that cell type in vivo. For neural induction: inhibit BMP and TGF-beta (dual SMAD inhibition). For cardiomyocytes: activate WNT then inhibit WNT. For pancreatic beta cells: activate Activin/Nodal → FGF → Notch inhibition → BMP in sequence. The order and timing of growth factors matters critically — adding BMP4 during neural induction will redirect cells toward mesoderm. Mouse and human stem cells differ in their signaling requirements (LIF/STAT3 for mouse naive pluripotency; FGF/ERK for human primed pluripotency), so protocols are not interchangeable. Organoids recapitulate some but not all organ features — always assess maturation state (fetal vs. adult gene expression) before drawing disease-relevance conclusions.
LOOK UP DON'T GUESS: Do not assume which markers define a target cell type or which signaling pathway drives differentiation — query CellMarker_search_by_cell_type for markers and kegg_search_pathway for the relevant pathway. Do not assume organoid fidelity; look up published CellxGene or HCA atlas data for comparison.
Key principles:
| Tool | Use For |
|------|---------|
| CELLxGENE_get_census_versions | Discover CELLxGENE Census release versions; then use CELLxGENE_get_cell_metadata / CELLxGENE_get_expression_data for specific cells / genes. Requires cellxgene-census package (pip install cellxgene-census). May not be installed by default. |
| CellMarker_search_by_cell_type | Cell type marker genes. Requires operation="search_by_cell_type", cell_name= (NOT cell_type=) |
| CellMarker_search_by_gene | Which cell types express a gene. Requires operation="search_by_gene", gene_symbol= |
| hca_search_projects | Human Cell Atlas organoid/development projects |
| GEO_search_rnaseq_datasets | Find stem cell RNA-seq datasets |
| kegg_search_pathway | Differentiation signaling pathways (WNT, Notch, Hedgehog) |
| ReactomeAnalysis_pathway_enrichment | Pathway analysis of stem cell gene sets |
| STRING_get_network | Pluripotency/differentiation gene networks |
| OpenTargets_get_associated_targets_by_disease_efoId | Disease genes for organoid disease modeling |
| PubMed_search_articles | Stem cell and organoid literature |
| search_clinical_trials | iPSC-based clinical trials |
Phase 0: Define the Question
Pluripotency? Differentiation? Disease modeling? Drug screening?
|
Phase 1: Cell Identity & Markers
CellMarker → pluripotency/lineage markers → verify identity
|
Phase 2: Differentiation Pathways
KEGG/Reactome → WNT, Notch, BMP, FGF signaling
|
Phase 3: Atlas & Dataset Discovery
CellxGene/HCA → reference datasets for target cell type
|
Phase 4: Disease Modeling (if applicable)
OpenTargets → disease genes → organoid recapitulation assessment
|
Phase 5: Report
Evidence-graded findings with clinical translation potential
Pluripotency markers (must be co-expressed): OCT4 (POU5F1), SOX2, NANOG (essential); SSEA-4, TRA-1-60 (human surface markers). KLF4 and MYC are Yamanaka factors but also expressed in somatic cells — do not rely on them alone. Use CellMarker_search_by_cell_type to retrieve the full validated marker set for any target cell type.
Lineage markers: Ectoderm → PAX6/SOX1 (early), MAP2/TUBB3 (neurons); Mesoderm → TBXT/MIXL1 (early), CD34 (blood); Endoderm → SOX17/FOXA2 (early), PDX1/NKX6.1 (pancreas). Retrieve current marker lists from CellMarker rather than relying on memory.
Key signaling pathways for directed differentiation:
| Pathway | KEGG ID | Role in Stem Cells | Common Modulators | |---------|---------|-------------------|-------------------| | WNT signaling | hsa04310 | Pluripotency maintenance (canonical) vs differentiation (non-canonical) | CHIR99021 (activator), IWP-2 (inhibitor) | | Notch signaling | hsa04330 | Lateral inhibition, fate decisions | DAPT (gamma-secretase inhibitor) | | BMP/TGF-beta | hsa04350 | Mesoderm/trophectoderm induction | BMP4 (activator), Noggin (inhibitor) | | FGF signaling | hsa04010 | Self-renewal, neural induction | bFGF (activator), SU5402 (inhibitor) | | Hedgehog | hsa04340 | Patterning, organoid maturation | SAG (activator), cyclopamine (inhibitor) | | Hippo/YAP | hsa04390 | Mechanotransduction, organoid size | Verteporfin (YAP inhibitor) |
# Find stem cell single-cell datasets
CELLxGENE_get_census_versions() # discover available Census releases, then use CELLxGENE_get_cell_metadata / CELLxGENE_get_expression_data
hca_search_projects(query="organoid")
GEO_search_rnaseq_datasets(query="iPSC differentiation neural", organism="Homo sapiens")
Organoid fidelity scoring — how well does the organoid recapitulate the organ?
| Feature | High Fidelity (3) | Moderate (2) | Low (1) | |---------|------------------|-------------|---------| | Cell type diversity | All major cell types present | Most cell types, missing rare ones | Only 1-2 cell types | | Architecture | Self-organized, correct spatial arrangement | Partial organization | Disorganized aggregate | | Function | Measurable organ function (secretion, contraction, electrophysiology) | Some functional markers | Marker expression only | | Maturation | Adult-like gene expression profile | Fetal-like | ESC-like (failed differentiation) | | Disease relevance | Recapitulates patient phenotype | Some disease features | No disease phenotype |
| Grade | Criteria | Example | |-------|---------|---------| | T1 | Clinical iPSC study or approved therapy | iPSC-derived RPE for macular degeneration (Mandai 2017) | | T2 | Functional validation (teratoma, engraftment, drug response) | Organoid drug screening with patient-specific response | | T3 | Marker expression + morphology | iPSC colony expressing OCT4/SOX2/NANOG | | T4 | Computational prediction or single-marker evidence | Predicted pluripotent by gene expression classifier |
tools
PCR / qPCR primer and oligo design — design forward/reverse primers for a target region (SantaLucia nearest-neighbor thermodynamics), compute melting temperature (Tm) and annealing temperature (Ta), check GC content, and screen an oligo for hairpins and primer-dimers. Use when you need primers for a sequence, want to QC an existing primer pair, or need the Tm of an oligo. Covers the primer-design rules (Tm matching, GC clamp, 3'-end, length) and the tools' constraint quirks.
tools
Pharmacokinetic (PK) analysis of concentration-time data — non-compartmental analysis (NCA) for Cmax, Tmax, AUC (0-t and 0-∞), terminal half-life, clearance (CL), volume of distribution (Vd), MRT, and absolute bioavailability (F). Also one-compartment fitting. Use when you have plasma/serum drug concentrations over time after a dose and need PK parameters, or to compute bioavailability from IV + oral AUCs. NOT for ADMET property prediction from structure (use tooluniverse-admet-prediction).
tools
Molecular cloning assembly design — Gibson Assembly (overlap design for seamless multi-fragment joining) and Golden Gate Assembly (Type IIS / BsaI / BbsI design with unique 4-bp fusion overhangs). Use when you need to plan how to join DNA fragments into a construct, design assembly overlaps/overhangs, or decide between cloning methods. Covers the domestication (internal-site removal), overhang-uniqueness, and overlap-Tm rules. For PCR primers to generate the fragments, see tooluniverse-primer-design.
tools
Meta-analysis / evidence synthesis — pool effect sizes across studies (odds ratios, risk ratios, hazard ratios, mean differences, correlations, GWAS betas) with fixed- or random-effects models, quantify heterogeneity (Q, I², τ²), and build a forest plot. Use when you have results from MULTIPLE studies and need a single pooled estimate, or to synthesize evidence from a systematic review / multiple GWAS / replicated experiments. Handles the error-prone effect-size + standard-error preparation (converting OR/HR/CI, two-group means±SD, proportions, and correlations into the (effect, SE) the pooling step needs).